Startseite Kongressberichte 2018 20th World Congress on Gastrointestinal Cancer (WCGIC 2018) Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer

Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer

A Multicentre, Prospective Clinical Evaluation Study For Analyzing RAS Mutational Status Utilizing Plasma Circulating Tumor DNA In Patients With Metastatic Colorectal Cancer
Yoshinori Kagawa, et al., O-005 

The authors of the study conclude that "The accuracy of plasma RAS mutational status determined by OncoBEAM RAS kit was confirmed for Japanese mCRC patients. The concordance rate between plasma- and tissue-based analyses was 86.4% in overall, rising to 89.2% in patients excluding lung metastasis alone, with 13.6% of discordant cases being potentially attributed to variables of tissue heterogeneity, a longer interval in sample collection from archived tissue to plasma and a lower amount of ctDNA shed into plasma. Careful attention should be paid for MCRC patients with lung metastases alone when considering the use of plasma ctDNA test instead of tissue-based test."


Ultra-selection of metastatic colorectal cancer patients using Next Generation Sequencing platform to improve the clinical efficacy of anti-EGFR therapy
Joana Vidal, et al., O-006

The authors of the study conclude that "this study analyses the impact of using an NGS platform for molecular diagnosis of mCRC patients. Increasing the sensitivity of MAF cutoff from 5% to 1% we identified mutations in RAS/BRAF hotspots in 27.63% more patients. Confirming results from our previous reports, no mutations in EGFR ECD have been detected in untreated samples."


Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: final results and translational analyses of the CRICKET study by GONO
Daniele Rossini, et al., O-007

The authors of the study conclude that "this is the first prospective demonstration of the activity of rechallenge with cetuximab(cet)+irinotecan in some mCRC patients initially sensitive and then resistant to first-line iri and cet-based therapy, with no RAS/BRAF mut in pre-treatment liquid biopsies. Partially funded by Merck Serono SpA."


The prognostic role of microsatellite status, tumor mutational burden and protein expression in CRC
Justina Lam, et al., O-008

The authors of the study conclude that " a combination of MSS, low TMB and low p16 expression characterized a subset of patients with longer survival. This is important because patients with MSS tumors have limited treatment options but may respond to CDK4/5 inhibitors due to low p16 expression. Molecular profiling of CRC may identify patient subgroups with a relatively poor prognosis who could benefit from personalized therapy."


A Phase II multi institutional study of Nivolumab in Patients with Advanced Refractory Biliary Tract Cancers (BTC)
Richard Kim, et al., O-009

The authors of the study conclude that "the primary endpoint of ORR was met. Nivolumab was well tolerated and has shown promising efficacy in refractory BTC including durable response lasting over 1 year. Further randomized trial is warranted in refractory BTC."

Cisplatin/5-Fluorouracil +/- Panitumumab for Patients with Non-resectable, Advanced or Metastatic Esophageal Squamous Cell Cancer: A Randomized phase III AIO/EORTC Trial with an Extensive Biomarker Program
Markus Moehler, et al., O-010

The authors of the study conclude that " To our knowledge, this has been the largest European first-line palliative phase III trial of chemotherapy +/- EGFR targeting agent in ESCC patients only. Addition of Panitumumab to CF provided no benefit to first-line CTX alone. A low sEGFR level was associated with better PFS and increased under CF+1Panitumumab. Further results of second-line therapies and further biomarker analysis will be presented at the meeting."